IJCS | Volume 31, Nº3, Maio / Junho 2018

307 26. Derzhko R, Plaksej R, Przewlocka-Kosmala M, Kosmala W. Prediction of left ventricular dysfunction progression in patients with a first ST- elevation myocardial infarction--contribution of cystatin C assessment. Coron Artery Dis. 2009;20(7):453-61. 27. Kilic T, Oner G, Ural E, Yumuk Z, Sahin T, Bildirici U, et al. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis. 2009;207(2):552- 8. doi: 10.1016/j.atherosclerosis.2009.05.015. 28. García Acuña JM, González-Babarro E, Grigorian Shamagian L, Peña- Gil C, Vidal Pérez R, López-Lago AM, et al. Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. Rev Esp Cardiol. 2009;62(5):510- 9. doi: 10.1016/S1885-5857(09)71833-X. 29. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman- Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145(4):237-46. doi: 10.7326/0003-4819-145-4- 200608150-00003. 30. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629-36. doi: 10.7326/0003-4819-134-8-200104170-00007. 31. Muntner P, He J, HammL, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13(3):745-53. PMID: 11856780. 32. Taglieri N, KoenigW, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem. 2009;55(11):1932-43. doi: 10.1373/clinchem.2009.128397. 33. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smoothmuscle cells. J Clin Invest. 1998;102(3):576-83. doi: 10.1172/JCI181. 34. Finney H, Bates CJ, Price CP. Plasma cystatin C determinations in a healthy elderly population. Arch Gerontol Geriatr. 1999;29(1):75-94. doi: https://doi.org/10.1016/S0167-4943 (99)00025-4. 35. Nunes GL. Avaliação da função renal em pacientes hipertensos. Rev Bras Hipertens. 2007;14(3):162-6. 36. Kirsztajn GM. Avaliação do ritmo de filtração glomerular. J Bras Patol Med Lab. 2007;43(4):257-64. doi:/ /http://dx.doi.org/10.1590 ?S1676-24442007000400007. 37. Bastos MG, Kirsztajn GM. Chronic kidney disease: importance of early diagnosis, immediate referral and structured interdisciplinary approach to improve outcomes in patients not yet on dialysis. J Bras Nefrol. 2011;33(1):93-108. doi: http://dx.doi.org/10.1590/S0101- 28002011000100013. 38. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci. 2004;41(5-6):467-550. doi: 10.1080/10408360490504934. 39. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004-13. doi: 10.1056/ NEJMra1216063. 40. Chan MY, Sun JL, Newby LK, Shaw LK, Lin M, Peterson ED, et al. Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. Circulation. 2009;119(24):3110-7. doi: 10.1161/CIRCULATIONAHA.108.799981. Martucheli et al. Cistatina C e síndromes coronarianas aguda International Journal of Cardiovascular Sciences. 2018;31(3)290-307 Artigo de Revisão Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons